We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Form of Press Release Sample Clauses

Form of Press Release eMagin Corporation (the “Company”) has entered into agreements, effective as of August 7, 2007 (the “Closing Date”), with Moriah Capital, L.P. (“Moriah”), pursuant to which the Company may borrow an amount not to exceed $2,500,000. Such funds may be drawn down by the Company in tranches of at least $25,000 up to five times each month. In connection with the transaction, the Company issued, executed and delivered to Moriah the following: · A Loan and Security Agreement; · A Secured Convertible Revolving Loan Note with a principal amount not to exceed $2,500,000; · A Loan Conversion Agreement; · A Securities Issuance Agreement pursuant to which the Company issued 162,500 shares of its common stock, which shares have an aggregate market value on the Closing Date of $195,000; · A Registration Rights Agreement; · An Intercreditor Agreement; and · A Post-Closing Agreement. Pursuant to the Loan and Security Agreement, the Company is permitted to borrow an amount not to exceed 90% of its eligible accounts (as defined in the agreements), net of all taxes, discounts, allowances and credits given or claimed, plus 50% of its eligible inventory capped at $600,000. As of August 9, 2007, pursuant to the Loan and Security Agreement, the Company has borrowed $607,500. The Company's obligations under the loans are secured by all of the assets of the Company, including but not limited to inventory and accounts receivable; provided, however, that Moriah’s lien on the collateral other than Accounts and Inventory (as such terms are defined in the agreements) are subject to the prior lien of the holders of the Company’s outstanding Amended and Restated 8% Senior Secured Convertible Notes Due 2008 in accordance with the terms of, and subject to the conditions set forth in the Intercreditor Agreement. The Loan and Security Agreement expires on August 7, 2008, but may be extended at the Company’s option for an additional one year period with the Company issuing additional shares of common stock to Moriah having an aggregate market value of $195,000 based on the average closing price of the Common Stock on the OTC Bulletin Board or such other trading market which such common stock is then listed or traded for the ten (10) trading days preceding the effective date of the extension of the initial term of the loan. Annual interest on the loans is equal to the greater of (i) the sum of (A) the Prime Rate as reported in the “Money Rates” column of The Wall Street Journal, adjusted as and...
Form of Press Release. MusclePharm Corporation [Date]
Form of Press Release. Universal Biosensors and Siemens Sign New Strategic Partnership to Launch Advanced Point-of-Care Coagulation Platform Contact:
Form of Press ReleaseXxxxxx Technology Corporation
Form of Press Release. InMode Ltd. [Insert date]
Form of Press Release. 12.2.1(a) BioNTech Core Patent Encumbrances 12.2.1(c) BioNTech Core Patents—Rights Granted to Third Parties 12.2.1(i) [***]
Form of Press Release. (See Attached) Merck and NewLink Genetics Enter into Licensing and Collaboration Agreement for Investigational Ebola Vaccine Clinical Development, Manufacturing Expertise, and Scale Critical to Success
Form of Press Release. Kornit Digital Ltd.
Form of Press Release. Mynaric AG [Date] Mynaric AG (the “Company”) announced today that Credit Suisse and Jefferies, the lead book-running managers in the Company’s recent public sale of [●] American Depositary Shares, representing an aggregate of [●] ordinary bearer shares of the Company, are [waiving] [releasing] a lock-up restriction with respect to [●] American Depositary Shares representing [●] ordinary bearer shares of the Company held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on [●], 20[●], and the American Depositary Shares and ordinary shares represented thereby may be sold on or after such date. Form of Lock-Up Agreement [Insert date] Mynaric AG Xxxxxxxxxxxxx 00 82205 Gilching Germany CREDIT SUISSE SECURITIES (USA) LLC XXXXXXXXX LLC As Representatives of the Several Underwriters, c/o Credit Suisse Securities (USA) LLC, Xxxxxx Xxxxxxx Xxxxxx, New York, N.Y. 10010-3629 Xxxxxxxxx LLC 000 Xxxxxxx Xxxxxx New York, N.Y. 10022 Ladies and Gentlemen: As an inducement to the underwriters to execute the Underwriting Agreement (the “Underwriting Agreement”), pursuant to which an offering (the “Offering”) will be made that is intended to result in the establishment of a public market for American Depositary Shares (the “ADSs”) representing ordinary bearer shares (no-par value shares) with a pro rata amount of the share capital attributable to each ordinary bearer share (auf die einzelne Aktie entfallender anteiliger Betrag des Grundkapitals) of €1.00 each (“Ordinary Shares” and, together with ADSs, the “Securities”) of Mynaric AG, a stock corporation (Aktiengesellschaft) under the laws of the Federal Republic of Germany, and any successor (by merger or otherwise) thereto, (the “Company”), the undersigned hereby agrees that during the period specified in the following paragraph (the “Lock-Up Period”), the undersigned will not, and will not cause any direct or indirect affiliate to, offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any Securities or securities convertible into or exchangeable or exercisable for any Securities, enter into a transaction which would have the same effect, or enter into any swap, hedge or other arrangement (including without limitation, any short sale or other purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed ...
Form of Press Release. Archemix and Takeda to Enter into Collaboration for Discovery and Development of Aptamer Therapeutics CAMBRIDGE, Mass. and OSAKA, Japan – June 11, 2007 – Archemix Corp. (“Archemix”) and Takeda Pharmaceutical Company Limited (“Takeda”) announced today that both parties have signed a multi-year, three target agreement that focuses on the discovery, development, and commercialization of first-in-class aptamer-based therapeutics. Under the agreement, Archemix will receive an upfront payment of $6 million from Takeda to discover and generate product candidates to three disease-associated targets identified by Takeda, and Takeda will be granted an exclusive, worldwide right for research, development, manufacturing and commercialization for any resulting aptamer-based products. Archemix will also receive committed research funding and research and clinical development milestone payments for each target selected for therapeutic development. In addition, Archemix will earn royalties and milestones on worldwide sales of the developed aptamers commercialized by Takeda. Detailed financial terms were not disclosed. “Our alliance with Takeda is the sixth major partnership we have formed over within the past year and is a major step in the continued validation of aptamer therapeutics,” said Xxxxx Xx Xxxxx, Ph.D., President and CEO, Archemix. “Takeda is an excellent partner for Archemix and this collaboration is a key component of successfully implementing our strategy of forming collaborations with multi national pharmaceutical companies to rapidly advance aptamer programs into clinical development.” “We are very impressed with Archemix’ track record of success in creating therapeutic aptamers,” said Xx. Xxxxxxxxx Xxxxxx, General manager of Pharmaceutical Research Division, Takeda. “Archemix is the leader in the discovery of aptamer therapeutics and we believe that, as a class, aptamers have the potential to create a new paradigm of treatments in a broad spectrum of diseases, and we believe this collaboration will surely contribute to enhancing our R&D pipeline as source for future growth of Takeda.” Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical stability, low immunogenicity and the ability to target prot...